Objective assessment of bradykinesia in Parkinson’s disease using evolutionary algorithms: clinical validation
- Submitting institution
-
University of York
- Unit of assessment
- 12 - Engineering
- Output identifier
- 66224036
- Type
- D - Journal article
- DOI
-
10.1186/s40035-018-0124-x
- Title of journal
- Translational Neurodegeneration
- Article number
- 18
- First page
- 18
- Volume
- 7
- Issue
- 1
- ISSN
- 2047-9158
- Open access status
- Compliant
- Month of publication
- August
- Year of publication
- 2018
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- Yes
- Number of additional authors
-
12
- Research group(s)
-
B - Intelligent Systems and Nano-Science
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- This paper reports clinical validation of a patented and CE Marked medical device (PD-Monitor) developed at York for assessment of symptoms in Parkinson’s disease. The device has supported a series of clinical trials to evaluate repurposed drugs for treating Parkinson’s: PD-STAT (Contact: Honorary consultant Neurologist, Plymouth), Exenatide-PD (Contact: Professor of Neurology, National Hospital) and AZA-PD (Contact: MRC Clinician Scientist, Cambrideg). The paper also shows how PD-Monitor can reliably differentiate Bradykinesia from Essential Tremor, a common neurological often mistaken for Parkinson’s disease that contributes to a 25% misdiagnosis rate (Rizzo et al. Neurology 86.6 (2016): 566-576).
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -